OGN Earnings

OGN reported its earnings on 2026-02-12, showcasing a revenue of 1.51B against an estimate of 1.53B, resulting in a -1.5% surprise. The EPS was 0.61, surpassing the expected 0.7 by -12.86%. The stock experienced a -8.19% price change on the earnings day and a -2.99% change over the next five days, reflecting market reactions to the results.

Following OGN's earnings announcement on 2026-02-12, the stock price moved by -8.19% on the day of the release. Over the subsequent five days, it saw a -2.99% change. Historically, OGN's stock price tends to shift by an average of 6.48% in the 10 days leading up to earnings and -1.91% in the 10 days following, providing insight into potential market.

For 2025/Q4, analysts estimate OGN's annual revenue to reach 1.52B, while the EPS is projected at 0.74. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between OGN's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were unchanged by 0%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, OGN's stock price typically moves by 6.48% in the 10 days before its earnings and -1.91% in the 10 days after. For the upcoming 2025/Q4 earnings, analysts expect an EPS of 0.74 and revenue of 1.52B.

The earnings call reveals several negative factors: declining revenue guidance, margin compression, and a net loss in Q4 2025. Despite growth in biosimilars and cost savings, these are overshadowed by underperformance in key areas like women's health and respiratory portfolio. Additionally, management's vague responses in the Q&A section, especially regarding the Audit Committee investigation, add uncertainty. The slight positive from biosimilars and cost savings isn't enough to outweigh these negatives, leading to an overall negative sentiment, likely resulting in a -2% to -8% stock price decline.